


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

HAMILTON et al.

Filed: December 3, 1998

Serial No: 09/204,238



For: **MULTIPLE HETEROATOM CONTAINING HETEROCYCLIC RING COMPOUNDS
SUBSTITUTED WITH CARBOXYLIC ACIDS AND ISOSTERES THEREOF**

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office are the following:

- 1) Transmittal Letter;
- 2) Response and Amendment;
- 3) Petition for 2-month Extension of Time; and
- 4) Check No. 12829 in the amount of \$380.00.

The Commissioner is hereby specifically authorized to charge any fee deficiency or credit any overpayment to our Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

Date: May 8, 2000



Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529

NATH & ASSOCIATES PLLC
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005-1503
Tel: (202) 775-8383
Fax: (202) 775-8396
GMN:TLJ:JBG:\ROA.TL

FILING RECEIPT

Attorney Docket No. AR138-X

Date: Dec. 30, 1999

Attorney: GMN/TLJ

Fee: \$0.00

Applicants: Gregory S. HAMILTON et al.

Serial No: 09/204,238

Filed: December 3, 1998

For:  MULTIPLE HETEROATOM CONTAINING HETEROCYCLIC RING COMPOUNDS SUBSTITUTED WITH CARBOXYLIC ACIDS AND ISOSTERES THEREOF

THE PTO STAMP HEREON ACKNOWLEDGES RECEIPT OF:

- 1) Transmittal letter; and
- 2) Letter to the Examiner.

NATH & ASSOCIATES

1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005-1503
TEL: (202) 775-8383
FAX: (202) 775-8396

FILE CHECK

Prepared by: HJ

Approved by: HJ

Copy Reviewed by: JBG

Filed by: _____

PATENT BOX
Attorney Docket No. AR138-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Gregory S. HAMILTON et al.

Group Art Unit: 1612


Serial No. 09/204,238

Examiner: Celia Chang

Filed: December 3, 1998

For: **MULTIPLE HETEROATOM CONTAINING HETEROCYCLIC RING COMPOUNDS SUBSTITUTED WITH CARBOXYLIC ACIDS AND ISOSTERES THEREOF**

TRANSMITTAL LETTER



Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal letter; and
- 2) Letter to the Examiner.

If extensions of time under 37 CFR § 1.136 other than those provided herewith are required to allow consideration of papers accompanying this Petition, then such extensions of time are hereby petitioned. The Commissioner is specifically authorized to charge fee deficiency under 37 CFR §§ 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES

Date: Dec. 30, 1999

By:



Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669

NATH & ASSOCIATES

1030 Fifteenth Street N.W.
Sixth Floor
Washington, D.C. 20005-1503
TEL: (202) 775-8383
FAX: (202) 775-8396

GMN:TLJ:JBG:\roadmap.t1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gregory S. HAMILTON et al.

Examiner: Celia Chang

Serial No: 09/204,238

Group: 1612

Filed: December 3, 1998



For: MULTIPLE HETEROATOM CONTAINING HETEROCYCLIC RING
COMPOUNDS SUBSTITUTED WITH CARBOXYLIC ACIDS AND ISOSTERES
THEREOF

LETTER TO THE EXAMINER
REGARDING INFORMATION DISCLOSURE STATEMENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants herein provide a brief description of material described in each reference cited in the Information Disclosure Statement, filed July 15, 1999; Supplemental Information Disclosure Statement, filed July 14, 1999; Third Supplemental Information Disclosure Statement filed October 8, 1999; and Fourth Supplemental Information Disclosure Statement filed October 21, 1999. A brief description of the material described in each reference cited in the Second Supplemental Information Disclosure Statement, filed October 8, 1999, was provided therewith. This outline is provided for the convenience of the Examiner and to advance the prosecution of the present application before the United States Patent and Trademark Office.

The Examiner's attention is drawn to the following IDS references containing biological information that the Examiner may find relevant for reviewing the subject matter of the present

invention. The identification letters shown below (**AD**, **AE**, etc.) refer to the reference line numbers cited in the respective Information Disclosure Statements.

Nerves- growth of; regeneration; degeneration:

Information Disclosure Statement:

AB.

First Supplemental Information Disclosure Statement:

AA, AB, AE, AH, AO, BD, BF, BG, BH, and BJ.

Third Supplemental Information Disclosure Statement:

AB, AC, AD, AE, AF, AG, AI, AJ, AK, AL, AM, AO, AP, AQ, AR, AS, AT, AU, AV, AW, BB, BN, BO, BR, BY, CL, DC, DG, and EF.

Fourth Supplemental Information Disclosure Statement:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AQ, AW, and BF.

Alzheimer's disease:

Information Disclosure Statement:

AB.

First Supplemental Information Disclosure Statement:

AA, AB, AE, AH, AN, AO, BB, BD, BF, BG, and BH.

Third Supplemental Information Disclosure Statement:

AB, AC, AE, AF, AG, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, BB, BN, BO, BR, BY, CL, DC, DG, and EF.

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AO, AP,
AQ, AW, AX, BE, and BF.**

Parkinson's disease:

Information Disclosure Statement:

AB.

First Supplemental Information Disclosure Statement:

AA, AB, AE, AH, AO, BD, and BG.

Third Supplemental Information Disclosure Statement:

**AB, AC, AE, AF, AG, AI, AJ, AK, AL, AO, AP, AQ, AR, AS,
AT, AU, AV, AW, BN, BO, BY, DC, DG, and EE.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AO, AW,
and BF.**

Amyotrophic lateral sclerosis:

Information Disclosure Statement:

AB and AC.

First Supplemental Information Disclosure Statement:

AA, AB, AE, AG, AH, AM, AN, BE, BG, and BI.

Third Supplemental Information Disclosure Statement:

**AB, AC, AE, AF, AG, AI, AJ, AK, AL, AM, AO, AP, AQ, AR,
AS, AW, BJ, BL, BP, and BY.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AH, AI, AJ, AK, AL, AN, AX, and
AW.**

Cerebral ischemia:

HAMILTON et al.
USSN 09/204,238

First Supplemental Information Disclosure Statement:

AB, AC, BB, and BK.

Third Supplemental Information Disclosure Statement:

AB, AC, AG, AI, AJ, AK, AN, AO, AP, AQ, AR, BN, BO, BR, CI, and EA.

Fourth Supplemental Information Disclosure Statement:

AL and AW.

Degenerative disorders of nervous system; CNS disorders:

Information Disclosure Statement:

AB.

First Supplemental Information Disclosure Statement:

AA, AE, AH, AL, AO, BB, BD, BF, and BH.

Third Supplemental Information Disclosure Statement:

AE, AF, AL, AP, AS, BI, BN, BR, CM, DC, EB, EE, EF, and EG.

Fourth Supplemental Information Disclosure Statement:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AM, AO, BA, BB, BC, and BD.

Memory or Dementia:

First Supplemental Information Disclosure Statement:

BB, BC, BF, and BH.

Third Supplemental Information Disclosure Statement:

AE, AF, AP, AQ, AT, AU, and BY.

Fourth Supplemental Information Disclosure Statement:

AO, AP, AQ, BC, BE, and BH.

Eye or vision, or similar disorders:

Information Disclosure Statement:

AC.

First Supplemental Information Disclosure Statement:

AA, AB, AD, AE, AG, AH, AI, AJ, AM, AN, AO, BE, BI, BJ,
and BK.

Third Supplemental Information Disclosure Statement:

AA, AM, AN, AP, AQ, BJ, BL, BP, BAC, CG, and CK.

Fourth Supplemental Information Disclosure Statement:

AN, AT, AV, and AX.

Hair Growth or Alopecia:

Information Disclosure Statement:

AA.

First Supplemental Information Disclosure Statement:

AC, AD and BA.

Third Supplemental Information Disclosure Statement:

AD, AG, AH, AM, AX, BA, BB, BC, BE, BG, BH, BQ, BS, BT,
BU, BW, BX, BZ, DB, DD, DE, and EH.

Fourth Supplemental Information Disclosure Statement:

AX.

The following references disclose chemical structures that the Examiner may find relevant for reviewing the subject matter of the present invention.

Information Disclosure Statement:

AA, AC, AD, AE, and AF.

First Supplemental Information Disclosure Statement:

AA, AG, AM, BE, BI, CA and CB.

Third Supplemental Information Disclosure Statement:

**AA, AB, AD, AF, AI, AL, AR, AY, AZ, BD, BF, BI, BJ, BK,
BL, BM, BV, BAA, BAB, CA, CB, CC, CD, CE, CF, CH, and DF.**

Fourth Supplemental Information Disclosure Statement:

AB, AG, AH, AK, AL, AM, AN, AR, AS, AU, BG, and BI.

Applicants have taken great care to ensure that the claims of the present invention are patentable over all cited references, but welcome and appreciate the Examiner's consideration of the same.

Please contact the undersigned attorney by telephone should there be any questions or comments.

Respectfully submitted,
NATH & ASSOCIATES

Date: Dec 30, 1999



Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669

NATH & ASSOCIATES

1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
(202) 775-8383
GMN:TLJ:JBG:\roadmap